Thelansis

Non-Tuberculous Mycobacterial (NTM) Market Outlook Thelansis’s “Non-Tuberculous Mycobacterial (NTM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Tuberculous Mycobacterial (NTM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Non-Tuberculous Mycobacterial (NTM) Overview Non-tuberculosis mycobacterial (NTM) lung infections, while less common than those caused by Mycobacterium tuberculosis, are transmitted via inhaled aerosolized droplets containing the infectious agents. Risk factors for NTM transmission include close living quarters, coughing, and failure to wear masks. Advanced age, immunosuppression, and corticosteroid...

 Non-Tuberculous Mycobacterial (NTM) are bacteria that are normally present in the environment. Inhalation of these bacteria may cause disease in both healthy patients and those with compromised immune systems. NTM disease most often affects the lungs in adults, but it may also affect any body site. Chronic pulmonary disease is the most common localized clinical manifestation of NTM. Mycobacterium avium complex, followed by M. kansasii, is the most frequent pathogen causing lung disease in the United States. Other pathogens occasionally causing pulmonary disease include M. abscessus, M. fortuitum, M. szulgai, M. simiae, M xenopi, M. malmoense, M. celatum, M. asiaticum, and M. shimodii. Except for patients with cystic fibrosis, children rarely develop this form of NTM disease, Although some NTM patients have a history of underlying chronic lung disease. The interpretation of NTM in the sputum of HIV-positive patients presents a particular problem, as these patients are frequently in...